Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds; Novo Nordisk’s move to discontinue an insulin leaves patients to ‘pick up the pieces’

Taking stock of the drug industry, from the lab to the medicine chest

April 24, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Biosimilars haven't always yielded lower out-of-pocket costs for patients, study finds "The fact that it's so hard to find savings consistently is disappointing," said Benjamin Rome, one of the study authors. By Ed Silverman STAT+ | Novo Nordisk's move to discontinue an insulin leaves patients to 'pick up the pieces' Novo Nordisk, known for blockbusters Ozempic and Wegovy, is discontinuing its Levemir insulin after a price cut, leaving patients in a bind. By Elaine Chen STAT+ | New studies suggest GLP-1 health care costs have only begun to climb Two new reports provide a window into the pressure that GLP-1 drugs could place on overall health care spending going forward. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser